Skip Navigation

Our PRIME IL-12 (RPTR 168) is an autologous multi-targeted T cell (MTC) investigational therapy that is tethered with IL-12. It is designed to provide an effective anti-tumor immune response in a broad set of cancer indications by targeting a set of five distinct tumor-associated antigens (TAA). Based on our pre-clinical studies, we believe that PRIME IL-12 provided both an autocrine response that promotes T cell function within immunosuppressed tumor microenvironments, and also stimulates neighboring immune cells in a paracrine manner to engage the endogenous immune system and promote broader anti-tumor immune activation. We expect our PRIME IL-12 to enter the clinic in early 2021.